AbbVie’s PARP inhibitor fails in PhIII trials

20th April 2017 Uncategorised 0

AbbVie’s experimental PARP inhibitor veliparib has failed to meet key targets in two late-stage studies testing its potential in lung and breast cancer.

More: AbbVie’s PARP inhibitor fails in PhIII trials
Source: News